Dear All, You may be interested to know that Open Access Journals and Articles are growing faster than subscription based. Below are the news items confirming the same. Open access comes of age A study of open-access publishing - published last week in the open-access journal PLoS ONE - has found that the number of papers in freely accessible journals is growing at a steady 20% per year (M. Laakso et al. PLoS ONE 6, e20961; 2011 http://dx.doi.org/10.1371/journal.pone.0020961 ). To many, the growth confirms the health of the free-access, author-pays model. But to a few it is a discouraging sign that open access is not about to take over the world of scholarly publishing. The analysis, by information scientist Mikael Laakso of the Hanken School of Economics in Helsinki and his colleagues, also found that the number of fully open-access journals is growing at around 15% every year as new journals are founded and subscription journals switch to the open-access model (see 'Opening up' http://www.nature.com/news/2011/110621/full/474428a/box/1.html ). By contrast, subscription journals are growing at about 3.5%. "Most indicators suggest growth is not slowing," says Laakso. "The open-access publishing model has proven itself to work." Read Further at http://www.nature.com/news/2011/110621/full/474428a.html?WT.ec_id=NATURE -20110623 The above Nature article is based on another article published in PLoS One Journal entitled "The Development of Open Access Journal Publishing from 1993 to 2009", which is available at http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.00209 61 You may also be interested in this blog post http://poynder.blogspot.com/2011/06/open-access-by-numbers.html Regards Madhuresh Singhal Manager - Knowledge Services Advinus Therapeutics Ltd 21 & 22, Phase 2, Peenya Industrial Area, Bangalore - 560058 Phone: +91 80 28394959 E-mail: madhureshsinghal@yahoo.com Visit us at Bio International Convention, 27 - 30 June 2011 in Washington DC., Booth# 1729 ************************************************************************************************* This email and its attachments are confidential and proprietary to Advinus Therapeutics Ltd. and are meant for the intended recipient only. If you are not the intended recipient, do not take any actions based on the contents of this message, except to permanently delete the message and its attachments and inform the sender immediately. ************************************************************************************************* -- This message has been scanned for viruses and dangerous content by MailScanner, and is believed to be clean.